HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

PSMA-1007

a PET imaging agent; structure in first source

Networked: 3 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Nicotinic Acids: 13
      - Niacinamide: 2223
        PSMA-1007: 3
- Heterocyclic Acids
  - Nicotinic Acids: 13
    - Niacinamide: 2223
      - PSMA-1007: 3
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - PSMA-1007: 3

Experts

1.	Chen, ShiRong: 1 article (01/2020)
2.	Cheng, ZhuZhong: 1 article (01/2020)
3.	Jiang, Xiao: 1 article (01/2020)
4.	Li, YingChun: 1 article (01/2020)
5.	Li, Zeng: 1 article (01/2020)
6.	Liao, Hong: 1 article (01/2020)
7.	Lu, Hao: 1 article (01/2020)
8.	Shen, TaiPeng: 1 article (01/2020)
9.	Wang, XiaoXiong: 1 article (01/2020)
10.	You, JinHui: 1 article (01/2020)

Related Diseases

1.

Prostatic Neoplasms (Prostate Cancer)

01/01/2020 - "18F labelled PSMA-1007 presents promising results in detecting prostate cancer (PC), while some pitfalls exists meanwhile. "
01/01/2022 - "Evaluation of a radiomics nomogram derived from Fluoride-18 PSMA-1007 PET/CT for risk stratification in newly diagnosed prostate cancer."
01/01/2022 - "Intraindividual Comparison Between [18F] PSMA-1007 PET/CT and Multiparametric MRI for Radiotherapy Planning in Primary Prostate Cancer Patients."

Related Therapies and Procedures

1.	Radiotherapy